|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2001, Vol. 98, No. 3, pp. 771-780
NEOPLASIA
Identifying intercellular signaling genes expressed in malignant
plasma cells by using complementary DNA arrays
John De Vos,
Guilhem Couderc,
Karin Tarte,
Michel Jourdan,
Guilhem Requirand,
Marie-Claude Delteil,
Jean-François Rossi,
Nadir Mechti, and
Bernard Klein
From INSERM U475, Unit for Cellular Therapy, and
Service d'Hématologie et d'Oncologie Médicale,
CHU Montpellier, France.
In multiple myeloma (MM), the growth of primary plasma cells
depends not only on interleukin-6 (IL-6), but also on additional unidentified signals delivered by the bone marrow environment. Using
Atlas complementary DNA (cDNA) arrays comprising 268 genes coding for
intercellular signaling molecules, this study identified genes that are
overexpressed in myeloma cells compared to autologous B-lymphoblastoid
cell lines. These genes encode the oncogenic Tyro3 tyrosine kinase
receptor, the heparin-binding epidermal growth factor-like growth
factor (HB-EGF) that is an epithelial autocrine tumor growth factor,
the thrombin receptor (TR) that is linked to HB-EGF and syndecan-1
processing and to cell invasion, chemokine receptors CCR1 and CCR2, the
Wnt pathway actor Frizzled-related protein (FRZB), and the
Notch receptor ligand Jagged 2. These data, obtained with the Atlas
cDNA array, were confirmed by reverse transcriptase-polymerase chain
reaction or protein analysis or both. Furthermore, Tyro3,
HB-EGF, TR, and FRZB gene
expression was documented in purified primary malignant plasma cells
from patients with plasma cell leukemia or MM. HB-EGF and FRZB were poorly expressed in purified polyclonal plasma cells. Finally, HB-EGF
was proved to be an essential autocrine growth factor for the XG-1
myeloma cells. This study shows the potency and the biologic relevance
of cDNA arrays used to analyze simultaneously a large panel of
intercellular signaling genes and, by identifying several genes
overexpressed in malignant plasma cells, opens new fields of
investigation in MM biology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood,
July 15, 2008;
112(2):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Pearse
Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6274s - 6278s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood,
August 1, 2005;
106(3):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Zhang, V. Vakil, M. Braunstein, E. L. P. Smith, J. Maroney, L. Chen, K. Dai, J. R. Berenson, M. M. Hussain, U. Klueppelberg, et al.
Circulating endothelial progenitor cells in multiple myeloma: implications and significance
Blood,
April 15, 2005;
105(8):
3286 - 3294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Ranheim, H. C. K. Kwan, T. Reya, Y.-K. Wang, I. L. Weissman, and U. Francke
Frizzled 9 knock-out mice have abnormal B-cell development
Blood,
March 15, 2005;
105(6):
2487 - 2494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Inoue, T. Otsuki, A. Hirasawa, I. Imoto, Y. Matsuo, S. Shimizu, M. Taniwaki, and J. Inazawa
Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple Myeloma
Am. J. Pathol.,
July 1, 2004;
165(1):
71 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Jundt, K. S. Probsting, I. Anagnostopoulos, G. Muehlinghaus, M. Chatterjee, S. Mathas, R. C. Bargou, R. Manz, H. Stein, and B. Dorken
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
Blood,
May 1, 2004;
103(9):
3511 - 3515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J.-F. Rossi, B. Klein, and K. Tarte
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
Blood,
April 15, 2004;
103(8):
3148 - 3157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
Blood,
March 1, 2004;
103(5):
1829 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Brocke-Heidrich, A. K. Kretzschmar, G. Pfeifer, C. Henze, D. Loffler, D. Koczan, H.-J. Thiesen, R. Burger, M. Gramatzki, and F. Horn
Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
Blood,
January 1, 2004;
103(1):
242 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Magrangeas, V. Nasser, H. Avet-Loiseau, B. Loriod, O. Decaux, S. Granjeaud, F. Bertucci, D. Birnbaum, C. Nguyen, J.-L. Harousseau, et al.
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease
Blood,
June 15, 2003;
101(12):
4998 - 5006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Lu, Y. Nakamoto, Y. Nemoto-Sasaki, C. Fujii, H. Wang, M. Hashii, Y. Ohmoto, S. Kaneko, K. Kobayashi, and N. Mukaida
Potential Interaction between CCR1 and Its Ligand, CCL3, Induced by Endogenously Produced Interleukin-1 in Human Hepatomas
Am. J. Pathol.,
April 1, 2003;
162(4):
1249 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, L. Smith, M. L. Hackbarth, I. W. Flinn, D. Young, J. H. Proffitt, and N. A. Heerema
Interphase Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia May Predict Response to Rituximab
Cancer Res.,
January 1, 2003;
63(1):
36 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-K. Hofmann, S. de Vos, M. Komor, D. Hoelzer, W. Wachsman, and H. P. Koeffler
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
Blood,
November 15, 2002;
100(10):
3553 - 3560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Blood,
July 30, 2002;
100(4):
1113 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Medh
Microarray-Based Expression Profiling of Normal and Malignant Immune Cells
Endocr. Rev.,
June 1, 2002;
23(3):
393 - 400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Greenstein, K. Ghias, N. L. Krett, and S. T. Rosen
Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies
Clin. Cancer Res.,
June 1, 2002;
8(6):
1681 - 1694.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
